Photo from wikipedia
MG1113 is a human monoclonal antibody of tissue factor pathway inhibitor (TFPI) under development for prophylaxis for hemophilia patients with or without inhibitors against factor VIII products, which have been… Click to show full abstract
MG1113 is a human monoclonal antibody of tissue factor pathway inhibitor (TFPI) under development for prophylaxis for hemophilia patients with or without inhibitors against factor VIII products, which have been used for the treatment of hemophilia. Because TFPI is a negative regulator in the extrinsic coagulation pathway, neutralization of TFPI function by MG1113 can potentially increase coagulation activity by bypassing the intrinsic coagulation pathway, which factor VIII activates.
Keywords:
disposition modeling;
antibody;
mediated drug;
tfpi;
target mediated;
drug disposition
Journal Title: Journal of Thrombosis and Haemostasis
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Thrombosis and Haemostasis
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!